Mylan N.V. (NASDAQ:MYL) has been given a $30.00 target price by equities researchers at Wells Fargo & Company in a research note issued on Wednesday. The brokerage presently has a “hold” rating on the stock. Wells Fargo & Company’s price target would indicate a potential downside of 7.09% from the stock’s previous close.
A number of other brokerages have also weighed in on MYL. Royal Bank Of Canada decreased their target price on shares of Mylan N.V. from $39.00 to $36.00 and set a “sector perform” rating for the company in a research note on Thursday, May 11th. Zacks Investment Research upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research note on Thursday, May 25th. BidaskClub upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Barclays PLC upgraded shares of Mylan N.V. from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $47.00 to $50.00 in a research note on Monday, May 22nd. Finally, Cowen and Company reiterated a “market perform” rating and set a $43.00 target price (down from $55.00) on shares of Mylan N.V. in a research note on Sunday, May 21st. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. Mylan N.V. has a consensus rating of “Buy” and a consensus price target of $47.83.
Mylan N.V. (NASDAQ:MYL) opened at 32.29 on Wednesday. Mylan N.V. has a one year low of $29.58 and a one year high of $49.42. The company has a market capitalization of $17.31 billion, a price-to-earnings ratio of 32.26 and a beta of 1.27. The firm’s 50-day moving average price is $37.57 and its 200 day moving average price is $39.05.
Mylan N.V. (NASDAQ:MYL) last announced its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.18 by $0.08. The company had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a net margin of 4.59% and a return on equity of 23.69%. Mylan N.V.’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.16 earnings per share. On average, equities research analysts expect that Mylan N.V. will post $4.86 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/11/mylan-n-v-nasdaqmyl-pt-set-at-30-00-by-wells-fargo-company.html.
In related news, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the transaction, the insider now owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, President Rajiv Malik sold 25,000 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the transaction, the president now directly owns 799,855 shares of the company’s stock, valued at approximately $31,994,200. The disclosure for this sale can be found here. Corporate insiders own 0.69% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Mylan N.V. by 3,447.5% in the first quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock valued at $1,513,696,000 after buying an additional 37,728,274 shares during the period. Pzena Investment Management LLC bought a new position in Mylan N.V. during the first quarter valued at approximately $283,158,000. TIAA CREF Investment Management LLC increased its position in Mylan N.V. by 187.3% in the first quarter. TIAA CREF Investment Management LLC now owns 4,315,668 shares of the company’s stock valued at $168,268,000 after buying an additional 2,813,653 shares during the period. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management bought a new position in Mylan N.V. during the second quarter valued at approximately $84,364,000. Finally, Morgan Stanley increased its position in Mylan N.V. by 82.6% in the first quarter. Morgan Stanley now owns 4,174,499 shares of the company’s stock valued at $162,765,000 after buying an additional 1,888,905 shares during the period. 70.19% of the stock is owned by institutional investors and hedge funds.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
